SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 16, 2025, Sarepta Therapeutics ( NASDAQ: SRPT ) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. The company also agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta's ELEVIDYS label. ELEVIDYS is the company's gene therapy drug intended to treat a limited category of people with Duchenne muscular dystrophy. The development comes in the wake of a securities class action styled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 1:25-cv-05317 (S.D.N.Y.), which seeks to represent investors who purchased or otherwise acquired Sarepta securities between June 22, 2023 and June 24, 2025.